Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1987 1
1988 1
1989 1
1990 1
1994 1
1996 4
1999 1
2000 1
2001 2
2002 2
2003 1
2004 1
2007 1
2010 1
2011 1
2012 1
2013 1
2014 4
2015 4
2016 6
2017 2
2018 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ; NOH301 Investigators. Kaufmann H, et al. Neurology. 2014 Jul 22;83(4):328-35. doi: 10.1212/WNL.0000000000000615. Epub 2014 Jun 18. Neurology. 2014. PMID: 24944260 Free PMC article. Clinical Trial.
At endpoint, supine systolic BP >180 mm Hg was observed in 4.9% of droxidopa and 2.5% of placebo recipients. Adverse events reported in 3% of double-blind droxidopa recipients were headache (7.4%) and dizziness (3.7%). ...CLASSIFICATION OF EVIDENCE: This study pr …
At endpoint, supine systolic BP >180 mm Hg was observed in 4.9% of droxidopa and 2.5% of placebo recipients. Adverse events report …
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Hauser RA, et al. Clin Neuropharmacol. 2016 Sep-Oct;39(5):220-6. doi: 10.1097/WNF.0000000000000168. Clin Neuropharmacol. 2016. PMID: 27332626 Free PMC article. Clinical Trial.
The 92 droxidopa patients reported 308 falls, and the 105 placebo patients reported 908 falls. ...Fall-related injuries occurred in 16.7% of droxidopa-treated patients and 26.9% of placebo-treated patients. CONCLUSIONS: Treatment with droxidopa appears to red …
The 92 droxidopa patients reported 308 falls, and the 105 placebo patients reported 908 falls. ...Fall-related injuries occurred in 1 …
Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Hauser RA, Hewitt LA, Isaacson S. Hauser RA, et al. J Parkinsons Dis. 2014;4(1):57-65. doi: 10.3233/JPD-130259. J Parkinsons Dis. 2014. PMID: 24326693 Clinical Trial.
At Week 1, mean dizziness/lightheadedness score change favored droxidopa by 1.5 units (p = 0.24), with subsequent numerical differences favoring droxidopa throughout the observation period, and at Week 1, mean standing systolic blood-pressure change favored droxi
At Week 1, mean dizziness/lightheadedness score change favored droxidopa by 1.5 units (p = 0.24), with subsequent numerical differenc …
Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB. Isaacson S, et al. J Am Soc Hypertens. 2016 Oct;10(10):755-762. doi: 10.1016/j.jash.2016.07.010. Epub 2016 Aug 4. J Am Soc Hypertens. 2016. PMID: 27614923 Free article. Clinical Trial.
A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2-1133 days). ...Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In t …
A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days ( …
Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals.
White WB, Hewitt LA, Mehdirad AA. White WB, et al. Clin Pharmacol Drug Dev. 2018 Mar;7(3):332-340. doi: 10.1002/cpdd.393. Epub 2017 Oct 11. Clin Pharmacol Drug Dev. 2018. PMID: 29024579 Free PMC article. Clinical Trial.
This study found no effect of either dose of droxidopa on cardiac repolarization using QTcI. Analysis of the pharmacokinetic/pharmacodynamic relationship and cardiac repolarization showed no association with droxidopa exposure. There were no clinically relevant effe …
This study found no effect of either dose of droxidopa on cardiac repolarization using QTcI. Analysis of the pharmacokinetic/pharmaco …
Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA. François C, et al. J Med Econ. 2016;19(5):515-25. doi: 10.3111/13696998.2015.1136827. Epub 2016 Jan 18. J Med Econ. 2016. PMID: 26710315 Free article. Clinical Trial.
OBJECTIVE: Falls are associated with neurogenic orthostatic hypotension (nOH) and are an economic burden on the US healthcare system. Droxidopa is approved by the US FDA to treat symptomatic nOH. This study estimates the cost-effectiveness of droxidopa vs standard o …
OBJECTIVE: Falls are associated with neurogenic orthostatic hypotension (nOH) and are an economic burden on the US healthcare system. Dro
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Biaggioni I, et al. BMC Neurol. 2017 May 12;17(1):90. doi: 10.1186/s12883-017-0867-5. BMC Neurol. 2017. PMID: 28494751 Free PMC article. Clinical Trial.
Droxidopa was effective in patients using inhibitors of dopa decarboxylase (DDCI; the enzyme that converts droxidopa to norepinephrine), but its efficacy was numerically greater in non-DDCI users. Droxidopa was well-tolerated. Rates of most adverse events wer
Droxidopa was effective in patients using inhibitors of dopa decarboxylase (DDCI; the enzyme that converts droxidopa to norepi
Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H; Droxidopa 302 Investigators. Biaggioni I, et al. Hypertension. 2015 Jan;65(1):101-7. doi: 10.1161/HYPERTENSIONAHA.114.04035. Epub 2014 Oct 27. Hypertension. 2015. PMID: 25350981 Free PMC article. Clinical Trial.
Droxidopa was well tolerated. In summary, this randomized withdrawal droxidopa study failed to meet its primary efficacy end point. Additional clinical trials are needed to confirm that droxidopa is beneficial in symptomatic neurogenic orthostatic hypotension
Droxidopa was well tolerated. In summary, this randomized withdrawal droxidopa study failed to meet its primary efficacy end p
Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Hauser RA, et al. Mov Disord. 2015 Apr 15;30(5):646-54. doi: 10.1002/mds.26086. Epub 2014 Dec 9. Mov Disord. 2015. PMID: 25487613 Clinical Trial.
At week 1, mean (standard deviation) improvement on OHSA item 1 was 2.3 (2.95) for droxidopa versus 1.3 (3.16) for placebo (P = 0.018). In addition, mean increase in s-SBP at week 1 was 6.4 (18.85) for droxidopa versus 0.7 (20.18) mmHg for placebo (nominal P value: …
At week 1, mean (standard deviation) improvement on OHSA item 1 was 2.3 (2.95) for droxidopa versus 1.3 (3.16) for placebo (P = 0.018 …
A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson's disease.
Zhao S, Cheng R, Zheng J, Li Q, Wang J, Fan W, Zhang L, Zhang Y, Li H, Liu S. Zhao S, et al. Parkinsonism Relat Disord. 2015 Oct;21(10):1214-8. doi: 10.1016/j.parkreldis.2015.08.023. Epub 2015 Aug 21. Parkinsonism Relat Disord. 2015. PMID: 26342560 Clinical Trial.

Individual motor symptoms such as stiffness, resting tremor, and alternate hand motion were also significantly improved with droxidopa on days 14 and 57 of treatment (P < 0.01 vs placebo), showing that droxidopa is effective in improving rigidity, tremor and alte

Individual motor symptoms such as stiffness, resting tremor, and alternate hand motion were also significantly improved with droxidopa
38 results